Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). - Bansal A; Stoffel EM; Lim R; Stanich PP; Patel SG; Burke CA; Hall MJ; Singh A; Boardman LA; Samadder NJ; Ballestar V; Muller C; et al. (Frontiers in immunology, 2026)